Independent guide · May 2026
Quick answer
Compounded semaglutide is a customized formulation of the active ingredient in Ozempic and Wegovy, prepared in a 503A licensed pharmacy under a licensed provider's prescription. It costs $99–$275 per month through telehealth providers — roughly 70–90% less than brand-name semaglutide. It is not FDA-approved as a finished drug but is legally prescribed when made from FDA-regulated active ingredients.
Compounded semaglutide is a personalized formulation of semaglutide — the active ingredient in Ozempic, Wegovy, and Rybelsus — prepared by a state-licensed compounding pharmacy under a licensed provider's prescription. It is not the same product as Ozempic or Wegovy, but it contains the same active ingredient.
Compounded semaglutide is legally prescribed when prepared in a 503A licensed pharmacy from FDA-regulated active ingredients. The active ingredient is the same as in Ozempic and Wegovy. Safety risk depends on the compounding pharmacy's licensure and quality control. Only use providers whose pharmacy partners are LegitScript-certified.
No. Compounded medications are not FDA-approved as finished drugs because they are personalized rather than mass-produced. They are legal under FDA section 503A when prepared by a state-licensed compounding pharmacy for a specific patient under a licensed provider's prescription.
Compounded semaglutide costs $99–$275 per month through telehealth providers in 2026. Pricing varies by provider, plan length, and inclusion of B12 or other additives. First-order pricing on 3- and 6-month plans typically starts at $99/month.
Both contain the same active ingredient. Ozempic is a manufactured FDA-approved diabetes drug from Novo Nordisk in fixed-dose pens. Compounded semaglutide is prepared per-prescription in a licensed pharmacy, often in a vial with provider-determined dose flexibility.
Compounded medications skip the manufacturer's R&D recovery, marketing budget, and patent-protected pricing. The active ingredient itself is the same. Telehealth providers can offer compounded semaglutide at $99/month because their pricing reflects active ingredient cost, pharmacy preparation, provider fee, and shipping — not brand-name pricing infrastructure.
Compounded semaglutide is prepared in a 503A licensed compounding pharmacy. The pharmacy receives the prescription from a licensed telehealth provider, sources FDA-regulated semaglutide active ingredient from an authorized supplier, and prepares the medication to the prescribed dose and concentration in a sterile environment.
The output is typically a multi-dose vial that lasts 4–8 weeks at the prescribed dose. Some compounded preparations include vitamin B12 — this can give the liquid a faint pink tint that is normal and not a quality indicator.
Compounded semaglutide must be prescribed by a state-licensed physician, nurse practitioner, or physician assistant after a medical evaluation. Telehealth providers structure the workflow so that intake, review, prescription, and dispensing all happen through licensed parties — but the prescription itself is between the patient and their assigned provider, not the platform.
Patients should be able to see the name and license number of their prescribing provider, and the name and license number of the dispensing compounding pharmacy. Providers that obscure either piece of information are a red flag.
Three checks matter most. First, verify the compounding pharmacy is LegitScript-certified — this is a public lookup. Second, check that the prescribing provider is licensed in your state by searching the state medical board database. Third, read independent reviews of the platform's actual patient experience, not their marketing.
Pricing alone is not a sufficient filter. The cheapest compounded semaglutide is usually around $99/month at first-order pricing. Below that price point, compromises on pharmacy quality or provider oversight become more likely.
Effectiveness depends on dose, adherence, and individual response. Patients typically follow a titration schedule similar to brand-name semaglutide: starting at 0.25 mg weekly and increasing every 4 weeks if tolerated, up to a target dose between 1.7 mg and 2.4 mg.
Most patients experience GI side effects (nausea, decreased appetite, occasional vomiting) during the first 2–4 weeks of each dose increase. Effects diminish as the body adapts. Patients should have access to their provider for dose adjustment if side effects persist.
Independently-rated telehealth providers we recommend for this medication. Sorted by editorial score.
Comprehensive GLP-1 programs with board-certified physicians and lab monitoring
Excellent
Highest-converting GLP-1 provider — $16 EPC, personalized consultations, tailored prescriptions
Excellent
Fastest-growing GLP-1 provider — oral, sublingual, and injectable options with Affirm financing
Excellent
150K+ members with 5 medication forms — injections, oral drops, lozenges, tablets, and pills
Very Good
See how compounded semaglutide compares to compounded tirzepatide, or read our head-to-head comparison.